Jacobio Pharmaceuticals Group Co (HKSE:01167) Cash-to-Debt : 5.45 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Jacobio Pharmaceuticals Group Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Jacobio Pharmaceuticals Group Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 5.45.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Jacobio Pharmaceuticals Group Co could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Jacobio Pharmaceuticals Group Co's Cash-to-Debt or its related term are showing as below:

HKSE:01167' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.45 Med: 21.26 Max: 224.36
Current: 5.45

During the past 6 years, Jacobio Pharmaceuticals Group Co's highest Cash to Debt Ratio was 224.36. The lowest was 5.45. And the median was 21.26.

HKSE:01167's Cash-to-Debt is ranked worse than
52.19% of 1527 companies
in the Biotechnology industry
Industry Median: 6.24 vs HKSE:01167: 5.45

Jacobio Pharmaceuticals Group Co Cash-to-Debt Historical Data

The historical data trend for Jacobio Pharmaceuticals Group Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Jacobio Pharmaceuticals Group Co Cash-to-Debt Chart

Jacobio Pharmaceuticals Group Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

15.31

152.71

224.36

8.69

5.45

Jacobio Pharmaceuticals Group Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial						224.36	373.32	8.69	6.40	5.45

Competitive Comparison of Jacobio Pharmaceuticals Group Co's Cash-to-Debt

For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jacobio Pharmaceuticals Group Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Jacobio Pharmaceuticals Group Co's Cash-to-Debt falls into.

Jacobio Pharmaceuticals Group Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Jacobio Pharmaceuticals Group Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1250.327	/	(96.192	+	133.407)
	=	5.45

Jacobio Pharmaceuticals Group Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1250.327	/	(96.192	+	133.407)
	=	5.45

Jacobio Pharmaceuticals Group Co (HKSE:01167) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Jacobio Pharmaceuticals Group Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Jacobio Pharmaceuticals Group Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Jacobio Pharmaceuticals Group Co (HKSE:01167) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

JBPHF:USA

Address

No. 88, Kechuang 6th Street, Building F2, Beijing Economic-Technological Development Area, Beijing, CHN

Website

http://www.jacobiopharma.com

Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of innovative oncology therapies.

Executives

Shen Zhu	2501 Other
Treasure Partner International Limited	2501 Other
Ultimate Estate Limited	2201 Interest of corporation controlled by you
Wang Yinxiang	2501 Other
Wang Xiaojie	2307 Founder of a discretionary trust who can infl
Hu Yunyan	2501 Other
Yakovpharma Ltd	2501 Other
Willgenpharma Ltd	2501 Other
Risepharma Ltd	2101 Beneficial owner
Johwpharma Ltd	2501 Other
Hmed Ltd	2501 Other
Gloryviewpharma Ltd	2501 Other
Honourpharma Ltd	2501 Other
Blesspharma Ltd	2501 Other
Hillhouse Investment Management, Ltd.	2102 Investment manager

Jacobio Pharmaceuticals Group Co (HKSE:01167) Headlines

No Headlines